Daniil Gataulin
Stock Analyst at Chardan Capital
(0)
# 4684
Out of 5,218 analysts
61
Total ratings
34.88%
Success rate
-18.84%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
CervoMed | Downgrades: Neutral | n/a | n/a | n/a | 3 | Dec 11, 2024 | |
Forte Biosciences | Maintains: Buy | 64 64 | 23.52 | 172.11% | 3 | Dec 4, 2024 | |
Outlook Therapeutics | Downgrades: Neutral | n/a | n/a | n/a | 7 | Dec 2, 2024 | |
Regenxbio | Maintains: Buy | 52 52 | 8.27 | 528.78% | 8 | Nov 20, 2024 | |
MeiraGTx Hldgs | Maintains: Buy | 36 36 | 6.12 | 488.24% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 6 6 | 0.87 | 589.66% | 7 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 6 6 | 1.01 | 494.06% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 11 11 | 0.49 | 2144.9% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 28 33 | 7.47 | 341.77% | 8 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 4 40 | 5.38 | 643.49% | 5 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 30 30 | 17.03 | 76.16% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 220 220 | 3.81 | 5674.28% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 22 13 | n/a | n/a | 2 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 5 3 | n/a | n/a | 2 | Sep 28, 2022 |